Date: 2013-10-08
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of research data at ICAAC 2013
Company: Fundación MEDINA (Spain) Cubist Pharmaceuticals (USA -MA)
Product: new antibiotics
Action mechanism:
Disease:
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On October 8, 2013, Fundación MEDINA and Cubist Pharmaceuticals have presented research data at ICAAC 2013 on a novel family of natural products antibiotics addressing the emerging threat from Gram-negative pathogens. Together scientists from Fundación MEDINA and Cubist Pharmaceuticals have discovered a new family of natural molecules that could serve as a scaffold to build next-generations antibiotics. These newly discovered molecules have unprecedented chemical structures and are completely different than antibiotics that have been or are currently being used by doctors. The results from this study were presented in September as a Poster (F1215), at ICCAC 53rd, Denver, Colorado. The data show that these compounds have specific in vitro activity against Gram-negative bacteria such as A. baumannii, P. aeruginosa and E. coli.
This new family of compounds was identified from a crude fermentation extract produced by a filamentous fungus. These results also show that these new molecules are believed to work by interfering with the process by which bacteria build their cells wall. The new family of molecules was discovered by scientists from Fundacion MEDINA of Granada, Spain, and Cubist Pharmaceuticals, Inc of Lexington, MA, USA, from a joint effort targeted at screening the microbial natural product libraries of Fundación MEDINA looking for new antibiotics to combat infectious diseases.
